Escolar Documentos
Profissional Documentos
Cultura Documentos
www. AJOG.org
OBSTETRICS
controlled trials (n 165) were eligible. Pooled latency period was 14.4
(range, 8.220.6) and 11.41 (range 3.4 to 26.2) days longer in the
TA group in the observational and the randomized controlled trials, respectively. Perinatal mortality rates were reduced among the treatment
groups in both the observational studies (odds ratio, 0.12; 95% confidence interval, 0.02 0.61) and the randomized controlled trials (odds
ratio, 0.33; 95% confidence interval, 0.10 1.12).
CONCLUSION: Serial TA for early PPROM may improve early PPROMassociated morbidity and mortality rates. Additional adequately powered randomized control trials are needed.
Cite this article as: Porat S, Amsalem H, Shah PS, et al. Transabdominal amnioinfusion for premature preterm rupture of membranes: a systematic review and
metaanalysis of randomized and observational studies. Am J Obstet Gynecol 2012;207:.
restrictive joint deformities. Chorioamnionitis negatively affects neonatal prognosis at all gestational ages and warrants
prompt delivery. The standard management approach to mid-trimester PPROM
includes antibiotic treatment2 and corticosteroids3 to accelerate fetal lung maturity
between 24 and 32 weeks of gestation.4
Delivery is warranted if there is clinical
evidence of chorioamnionitis or fetal distress. Termination of pregnancy may be
offered for previable PPROM (22-23
weeks of gestation) because of the poor
prognosis. Despite the relatively high frequency of this condition, controversy regarding the optimal management persists.
In recent years, attempts to decrease
neonatal mortality and morbidity rates
were undertaken with different strategies
that included intracervical fibrin application,5 amniopatch,6 fetal endoscopic
tracheal occlusion,7,8 antioxidant treatment,9 gelatin sponge,10 and progesterone treatment.11 None of these strategies
have proved to be consistently effective, reproducible, or applicable for
most centers.
1.e1
Research
Obstetrics
www.AJOG.org
outcomes of interest were pulmonary
hypoplasia, neonatal death, gestational
age at birth, birthweight, chorioamnionitis, early onset (72 hours from delivery) neonatal sepsis, bronchopulmonary
dysplasia, and cesarean delivery. Two investigators (S.P. and H.A.) independently abstracted the relevant data from
selected articles.
FIGURE 1
M ETHODS
Search strategy
We performed a comprehensive literature
search, assisted by an experienced librarian, using the MEDLINE from 1950 to December 2011 and EMBASE from 1980 to
December 2011. We also searched the
ClinicalTrials.gov database for studies
that finished recruitment. We used the
terms fetal membranes, premature rupture, rupture, membrane*, pregnancy,
amnioinfus*, premature fetus membrane
rupture, and amnioinfusion. There were
no language or geographic restrictions.
1.e2
Study selection
We included both comparative observational and RCTs in which TA and conventional treatment were compared with conventional treatment alone. Case reports,
case series, and abstract publications were
excluded. Studies that included patients
with a confirmed diagnosis of PPROM-associated oligohydramnios were included.
Studies that included oligohydramnios
from other causes (eg, intrauterine
growth restriction, renal anomalies)
were excluded. Two reviewers (S.P. and
H.A.) independently evaluated studies for
inclusion; disagreements were resolved
through consensus among the authors.
Outcome measures
The primary outcomes of interest were
latency period (interval from PPROM to
birth) and perinatal death. Secondary
Data extraction
Data were extracted in duplicate from
published reports by 2 authors who used
a standardized data collection form. A
third reviewer was consulted in case of
disagreement between the 2 data extractors; discrepancy was resolved by consensus. We did not contact authors for
missing information. For continuous
outcomes, means and standard deviations were obtained from studies. When
they were not reported, they were calculated from range, median, and sample
size according to the method described
by Hozo et al.21 For categoric outcomes,
event rates were obtained.
Statistical analysis
Statistical analyses were performed with
the Review Manager (RevMan) software
(version 5.1.4; The Nordic Cochrane
Centre, Kbenhavn, Denmark). Metaanalyses were performed separately for
cohort studies and the RCTs. Where data
were sufficiently homogenous, metaanalysis was conducted with the use of a
random effects model, with weighting of
studies according to the DerSimonianLaird method. Random-effect model
was used to account for between and
within study heterogeneity. Cochrans Q
Obstetrics
www.AJOG.org
Research
TABLE 1
Characteristics
17
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Quasi-randomized; patients admitted by chance to 1 of 2 divisions of the same department; both divisions
offered expectant treatment; only 1 division offered TA
.......................................................................................................................................................................................................................................................................................................................................................................
Participants
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
Singleton; PPROM at 26 weeks of gestation; severe and persistent oligohydramnios (AFI 30 mm, lasting 7 d)
Exclusion criteria
Clinical chorioamnionitis; active labor; autoimmune or metabolic disease; history of multiple invasive procedures;
declining treatment after informed consent; delivery in the interim 7-day waiting period from admission; transfer
from other hospitals after a period of treatment
..............................................................................................................................................................................................................................................................................................................................................................
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Hospital bed rest; antibiotic prophylaxis (mezlocillin, 2 g intravenously twice daily for at least 7 days) or targeted
treatment based on cultures; tocolytic treatment (isoxsuprine, either intravenously or orally) for contractions;
betamethasone after 25 weeks; fetal monitoring by daily heart check or cardiocotography after 26 weeks and
modified BPP every 3 days; cesarean delivery performed in the presence of chorioamnionitis, abruptio placentae,
and/or fetal distress (abnormal fetal monitoring) or at 30 weeks of gestation
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
Weekly saline amnioinfusion in a sufficient amount to increase AFI to 10 cm starting 7 days at least after
PPROM; antibiotics and tocolysis on the day of amnioinfusion
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Latency period; gestational age at delivery; cesarean delivery; genitourinary infection, amnionitis/endometritis;
neonatal weight; orotracheal intubation; survival; deformities; pulmonary hypoplasia; bronchopulmonary
dysplasia; early-onset sepsis; early-onset pneumonitis; abnormal neurologic outcome (includes cerebral palsy,
spastic diplegia or tetraplegia, deafness, or blindness)
.......................................................................................................................................................................................................................................................................................................................................................................
Notes
Also included were women who underwent PROM after amniocentesis for prenatal diagnosis: 10 patients
(27.0%) in the amnioinfusion group and 8 patients (23.5%) in the control group
................................................................................................................................................................................................................................................................................................................................................................................
35
Tranquilli et al 2005
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Participants
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
Singleton pregnancy with a certain gestational age confirmed by an early second-trimester ultrasonographic
examination; gestational age 24-33 weeks; evidence of PPROM within 24 hours of admission; oligohydramnios
(amniotic fluid index, 10th percentile); absence of uterine contractions at the time of hospitalization; no
evidence of clinical chorioamnionitis at admission; no evidence of placental anomalies or major structural fetal
anomalies, and normal cardiotocography at the time of admission
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
PPROM diagnosed on examination by a sterile speculum when obvious leakage of amniotic fluid from the
cervical os was confirmed by a positive fibronectin test
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Hospital bed rest; antibiotic prophylaxis (sulbactam-ampicillin 3 g, intravenously every 8 hours for 7 days);
betamethasone therapy; prophylactic tocolytic (intravenous ritodrine) in the absence of clinical signs of
chorioamnionitis or placental abruption; daily fetal heart rate monitoring
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
Weekly serial amnioinfusion if the AFI fell 5th percentile and/or a median pocket of amniotic fluid was 2 cm,
with a target AFI of 10th percentile; if repeated AFI was 5, amnioinfusion repeated weekly until 27 weeks of
gestation; a nonstress test performed daily
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Latency period; gestational age at delivery; birthweight; admission to neonatal intensive care unit; pulmonary
hypoplasia; abnormal neurologic outcome
................................................................................................................................................................................................................................................................................................................................................................................
34
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Participants
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
Singleton pregnancy; PPROM between 26 and 33 6 week gestations; AFI 5th percentile for gestational age
Exclusion criteria
Women with evidence of clinical chorioamnionitis, placental or fetal anomalies; active labor or AFI 5th percentile
..............................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
(continued )
1.e3
Research
Obstetrics
www.AJOG.org
TABLE 1
Characteristics
Diagnosis of PPROM
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
24 hours of observation after admission before randomization; hospital bed rest; antibiotic prophylaxis
(erythromycin: 250-mg tablet 4 times per day for 10 days); betamethasone prophylaxis; daily obstetric
examination; weekly BPP, complete blood cell count, and cervical/vaginal cultures
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
Amnioinfusion of warmed saline solution in a sufficient amount to maintain the AFI at 5th percentile for
gestational age; weekly AFI measurement and repeated amnioinfusion if the AFI fell 5th percentile; labor
induction when there was fetal distress or chorioamnionitis
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Latency period; gestational age at delivery; birthweight; intrapartum fetal distress; early neonatal sepsis; rate
and causes of neonatal mortality; type and mode of delivery; postpartum sepsis
................................................................................................................................................................................................................................................................................................................................................................................
33
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Observational
Participants
18 patients in intervention group and 16 patients in historic cohort group who did not undergo the procedure
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
..............................................................................................................................................................................................................................................................................................................................................................
Exclusion criteria
Amniotic fluid leakage after second-trimester amniocentesis; clinical chorioamnionitis; presence of uterine
contractions 4/hour; sonographic diagnosis of structural fetal abnormalities; maternal immunologic diseases;
multiple gestations
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
Observation of vaginal pooling and a positive nitrazine test on sterile speculum examination
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Hospital bed rest during the first week, then home bed rest until 25 weeks, after which all patients were
admitted until delivery; tocolytic treatment (intravenous ritodrine) given at 25 weeks for uterine contractions in
the absence of clinical signs of chorioamnionitis or abruption placentae; betamethasone course at least once
between 25 and 32 weeks of gestation; 1-week course of prophylactic antibiotic therapy with sulbactamampicillin 3 g intravenously every 8 hours and targeted treatment based on cervical and vaginal cultures;
sonographic determination of amniotic fluid volume twice a week for outpatients and daily for inpatients; BPP
twice a week at 25 weeks of gestation
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
1-2 TA/wk to aim to restore AFI 5 cm; delivery in the presence of clinical chorioamnionitis, fetal distress,
abruption placentae, or documented fetal lung maturity on amniocentesis after 28 weeks of gestation
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Gestational age at delivery; latency period; survival rate; pulmonary hypoplasia; chorioamnionitis; fetal distress;
placental abruption; preterm labor; in utero death; umbilical cord prolapse
................................................................................................................................................................................................................................................................................................................................................................................
30
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Observational
Participants
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
Singleton; PPROM between 25 and 32 weeks of gestation; oligohydramnios (AFI, 5th percentile)
Exclusion criteria
..............................................................................................................................................................................................................................................................................................................................................................
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
Observation of gross vaginal pooling of amniotic fluid and a positive nitrazine test on speculum examination
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Hospital bed rest until delivery with minimal activity limited to bathroom necessities; weekly complete blood cell
count and semiquantitative C-reactive protein measurement; weekly ultrasound scanning and cardiocotography;
daily nonstress test; prophylactic tocolytic treatment (intravenous ritodrine) in the absence of chorioamnionitis or
abruption placentae; prophylactic antibiotic treatment (ceftazidime 2 g/d intramuscularly) and targeted therapy
based on cultures; delivery in the presence of clinical chorioamnionitis, positive amniotic fluid culture, fetal
distress, and documented fetal lung maturity
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
If AFI 10th percentile for gestational age and deepest pocket of cord-free fluid 10 mm, weekly TA of 150350 mL warmed saline solution; weekly AFI assessment before and after each procedure; biweekly fetal growth
assessment
................................................................................................................................................................................................................................................................................................................................................................................
1.e4
(continued )
Obstetrics
www.AJOG.org
Research
TABLE 1
Characteristics
Outcomes
Latency period duration; median amniotic fluid volume and short-term variability; relationship between amniotic
fluid volume and fetal short-term variability in the amnioinfusion group
................................................................................................................................................................................................................................................................................................................................................................................
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Observational
Participants
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
PPROM at gestational age 27 weeks; oligohydramnios with AFI 5 cm; normal fetal anatomic scan; absence
of gross infection; stable mother and fetus
..............................................................................................................................................................................................................................................................................................................................................................
Exclusion criteria
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Initial hospital bed rest, followed by outpatient follow-up evaluation for stable patients; corticosteroids after 24
weeks of gestation; magnesium sulfate and terbutaline were used for tocolysis as needed if preterm labor
suspected in the absence of clinical chorioamnionitis; prophylactic intravenous antibiotics
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
Before the procedure, intravenous magnesium sulfate 4 g loading dose followed by 1 g/hr was initiated and
discontinued 12 hours after the procedure if preterm labor did not ensue; weekly amnioinfusion of warm 0.9%
normal saline solution with ampicillin 1 g/L until 27 weeks of gestation if AFI 5
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Chorioamnionitis; latency period; cesarean delivery rate; gestational age at delivery; birthweight; neonatal sepsis;
neonatal death; perinatal death; total death
................................................................................................................................................................................................................................................................................................................................................................................
31
.......................................................................................................................................................................................................................................................................................................................................................................
Type of study
Observational
Participants
.......................................................................................................................................................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................................................................................................................................
Inclusion criteria
Exclusion criteria
..............................................................................................................................................................................................................................................................................................................................................................
.......................................................................................................................................................................................................................................................................................................................................................................
Diagnosis of PPROM
.......................................................................................................................................................................................................................................................................................................................................................................
Interventions
..............................................................................................................................................................................................................................................................................................................................................................
All
Tocolytic treatment (ritodrine) for 4 uterine contractions/20 min; betamethasone after 24 weeks of gestation;
prophylactic antibiotic therapy (erythromycin 2 g/d) given to 90% of patients
..............................................................................................................................................................................................................................................................................................................................................................
Intervention
TA of 0.9% normal saline solution or lactated Ringers solution according to a volume criterion of 10
mL/gestational week; repeated if AFI measurement 12 hours after the procedure was 5 cm
.......................................................................................................................................................................................................................................................................................................................................................................
Outcomes
Gestational age at delivery; latency period; birthweight; rate of intrauterine death, vaginal bleeding, cesarean
delivery, and postpartum endometritis
.......................................................................................................................................................................................................................................................................................................................................................................
Notes
Refers to a group of patients in whom the oligohydramnios was not attributed to PPROM; however, all data cited
refer only to patients affected by PPROM
................................................................................................................................................................................................................................................................................................................................................................................
AFI, amniotic fluid index; BPP, biophysical profile; CBC, complete blood cell count; PPROM, preterm premature rupture of membranes; TA, transabdominal amnioinfusion.
Porat. Transabdominal amnioinfusion for PPROM. Am J Obstet Gynecol 2012.
test was used to test for heterogeneity between studies at the .10 level of significance. The I-squared statistic was used to
quantify the degree of heterogeneity.
Report
Results of the metaanalysis of RCTs and
the observational studies were reported
according to the Preferred Reporting
Items for Systematic Reviews and Metaanalyses statement22 and Metaanalysis of
R ESULTS
Our initial search yielded 141 citations.
After review of titles and abstracts, 126
citations were excluded (Figure 1). After
full text review of the remaining 15
articles, 8 articles were excluded (3 because inclusion criteria were not fulfilled13,14,24; 4 because of it was not
1.e5
Research
Obstetrics
www.AJOG.org
TABLE 2
Comparability
Ascertainment
of exposure
Demonstration
that outcome of
interest was not
present at start
of study
Ogunyemi and
Thompson
(2002)32
Vergani et al
(1997)33
Garzetti et al
(1997)30
Gramellini et al
(2003)31
Study
Comparability of
cohorts on the
basis of the
design or
analysis
**
Outcome
Assessment
of outcome
Was follow-up
long enough
for outcomes
to occur?
Adequacy of
follow up of
cohorts
Total
stars,
n
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
**
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
Each asterisk represents 1 star in the Newcastle-Ottawa Scale system. The maximum number of stars is 2 for comparability and 1 for each of the other categories.
Porat. Transabdominal amnioinfusion for PPROM. Am J Obstet Gynecol 2012.
1 study was quasirandomized (34 patients in the control group and 37 in the
intervention group), and 4 studies were
observational studies (75 patients in the
control group and 72 in the intervention
group). In the quasirandomized study,
patients were admitted by chance to one
of 2 departments that differed in their
management approach toward PPROM:
one department provided standard care;
the other department provided standard
care in addition to serial amnioinfusion
to consented patients. We decided to include the quasirandomized study with
the other 2 randomized studies because
we believed that the risk of bias in that
study was not high. The gestational age at
inclusion varied from 16-33 weeks. Information on individual patients was
provided only in 1 study32; therefore,
subgroup analysis by gestational age was
number of procedures per patient, success rate, and volumes infused varied
among different studies and among different subjects in the same study. The average number of infusions per patient
ranged from 1.23 in Singla et al34 to 4.0 in
De Santis et al.17 Vergani et al33 reported
a median number of 3 infusions per patient with a range of 19. Most of the
studies did not report success rate;
however, Garzetti et al30 reported a
success in 18 of 19 patients, and De
Santis et al17 reported successful amnioinfusion in 143 of 147 procedures.
The infused volumes range from 140350 mL per infusion.17,30,34,35
De Santis et al17 reported on 5 complications that occurred within 24 hours after infusion: 2 cord prolapses (1 cephalic
and 1 transverse lie); 2 abruptio placentae, and 1 onset of labor. Gramellini et
TABLE 3
Allocation
concealment
Performance: blinding
of participants
and personnel
Detection: blinding
of outcome
assessment
Attrition: incomplete
outcome data
Reporting:
selective
reporting
Other
sources
Overall
Singla et al
(2010)34
Low risk
Unclear risk
Unclear
Unclear
Low risk
Low risk
Low risk
Moderate risk
Tranquilli et al
(2005)35
Low risk
De Santis et al
(2003)17
High risk
Study
................................................................................................................................................................................................................................................................................................................................................................................
Low risk
Unclear
Unclear
Low risk
Low risk
Low risk
Moderate risk
................................................................................................................................................................................................................................................................................................................................................................................
High risk
Unclear
High risk
Low risk
Low risk
Low risk
High risk
................................................................................................................................................................................................................................................................................................................................................................................
1.e6
Obstetrics
www.AJOG.org
Research
FIGURE 2
Forest plot of the results of the metaanalysis of observational studies for A, latency period length, which demonstrates the difference in latency period
lengths between the TA and control groups; B, perinatal mortality rates refer to the odds ratio; and C, pulmonary hypoplasia refers to the odds ratio.
TA, transabdominal amnioinfusion.
Porat. Transabdominal amnioinfusion for PPROM. Am J Obstet Gynecol 2012.
Metaanalyses of observational
studies
Primary outcomes
There was prolongation of the latency
period (4 studies, 147 participants; mean
difference, 14.4 days; 95% confidence interval [CI], 8.220.6 days; heterogeneity:
I2 17%; Figure 2) and reduction in
perinatal mortality rate (2 studies, 60
1.e7
Research
Obstetrics
www.AJOG.org
TABLE 4
Studies/participants, n
4/147
3/111
4/147
Effect estimate
Studies/participants, n
Effect estimatea
3/165
................................................................................................................................................................................................................................................................................................................................................................................
3/165
................................................................................................................................................................................................................................................................................................................................................................................
14.40 (8.2420.56)
3/165
................................................................................................................................................................................................................................................................................................................................................................................
2/77
3/165
................................................................................................................................................................................................................................................................................................................................................................................
2/60
0.12 (0.020.61)
2/131
0.33 (0.101.12)
Pulmonary hypoplasia
2/45
0.17 (0.040.78)
2/69
0.30 (0.051.70)
Amnionitis/endometritis
3/111
0.94 (0.332.68)
2/131
0.28 (0.110.69)
1/18
0.10 (0.002.35)
2/83
0.38 (0.026.07)
1/18
0.09 (0.010.84)
3/129
0.52 (0.073.76)
Bronchopulmonary dysplasia
1/18
2.14 (0.0860.17)
1/20
7.67 (0.32183.01)
Genitourinary infection
N/A
1/71
1.29 (0.493.42)
Cesarean delivery
2/54
1/71
2.35 (0.816.81)
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
N/A
................................................................................................................................................................................................................................................................................................................................................................................
4.16 (0.9617.95)
................................................................................................................................................................................................................................................................................................................................................................................
Data are given as odds ratio (95% confidence interval); b The first 4 rows of data represent mean difference with 95% confidence interval, the rest of the rows represent odds ratio with 95% confidence
interval.
Metaanalyses of RCTs
Primary outcomes
There was no statistically significant difference in the latency period (3 studies,
165 participants; mean difference, 11.4
days increase in latency in TA group;
however, 95% CI 3.4 to 26.2 days; heterogeneity: I2 89%; Figure 3) and no
statistically significant difference in perinatal mortality rate (2 studies, 131 participants; pooled OR, 0.33; 95% CI,
0.10 1.12; heterogeneity: I2 45%; Figure 3). A subgroup analysis of periviable
vs potentially viable babies could not be
performed because of a lack of reporting
data.
Secondary outcomes
Results of metaanalyses of secondary
outcomes are given in Table 4. There was
no statistically significant difference in
the rate of pulmonary hypoplasia (2
studies, 69 participants; pooled OR, 0.3;
95% CI, 0.051.7; heterogeneity: I2
52%; Figure 3).
1.e8
C OMMENT
Mid-trimester PPROM poses a challenging clinical problem. Poor prognosis
usually results from the combination of
prematurity, pulmonary hypoplasia, and
infection. The prognosis of mid-trimester PPROM at 21 weeks of gestation is
grave because most fetuses experience
pulmonary hypoplasia.36 Pregnancy outcomes are correlated directly with the
gestational age at which the membranes are ruptured and the amount
of residual fluid after the rupture of
membranes. Low residual volume of
amniotic fluid has been shown to be
associated with a shorter latency period37,38 and increased risk for early
onset neonatal sepsis and chorioamnionitis.37 Lack of an effective treatment or intervention to prolong pregnancy complicates this situation even
further. Despite the seriousness and
Obstetrics
www.AJOG.org
Research
FIGURE 3
Forest plot of the results of the metaanalysis of randomized controlled trials for A, latency period length, which demonstrates the difference in latency period
lengths between the TA and control groups; B, perinatal mortality rates refer to the odds ratio; and C, pulmonary hypoplasia refers to odds ratio.
TA, transabdominal amnioinfusion.
Porat. Transabdominal amnioinfusion for PPROM. Am J Obstet Gynecol 2012.
1.e9
Research
Obstetrics
REFERENCES
1. Mercer BM. Preterm premature rupture of
the membranes: current approaches to evaluation and management. Obstet Gynecol Clin
North Am 2005;32:411-28.
1.e10
www.AJOG.org
2. Yudin MH, van Schalkwyk J, Van Eyk N, et al.
Antibiotic therapy in preterm premature rupture
of the membranes. J Obstet Gynaecol Can
2009;31:863-74.
3. Harding JE, Pang J, Knight DB, Liggins GC.
Do antenatal corticosteroids help in the setting
of preterm rupture of membranes? Am J Obstet
Gynecol 2001;184:131-9.
4. Miracle X, Di Renzo GC, Stark A, Fanaroff A,
Carbonell-Estrany X, Saling E. Guideline for the
use of antenatal corticosteroids for fetal maturation. J Perinat Med 2008;36:191-6.
5. Sciscione AC, Manley JS, Pollock M, et al. Intracervical fibrin sealants: a potential treatment for
early preterm premature rupture of the membranes. Am J Obstet Gynecol 2001;184:368-73.
6. Deprest J, Emonds MP, Richter J, et al. Amniopatch for iatrogenic rupture of the fetal membranes. Prenat Diagn 2011;31:661-6.
7. Kohl T, Geipel A, Tchatcheva K, et al. Lifesaving effects of fetal tracheal occlusion on pulmonary hypoplasia from preterm premature
rupture of membranes. Obstet Gynecol 2009;
113:480-3.
8. Kohl T, Muller A, Franz A, et al. Temporary
fetoscopic tracheal balloon occlusion enhanced by hyperoncotic lung distension: is
there a role in the treatment of fetal pulmonary
hypoplasia from early preterm premature rupture of membranes? Fetal Diagn Ther 2007;
22:462-5.
9. Borna S, Borna H, Daneshbodie B. Vitamins
C and E in the latency period in women with
preterm premature rupture of membranes. Int J
Gynaecol Obstet 2005;90:16-20.
10. OBrien JM, Milligan DA, Barton JR. Gelatin
sponge embolization. a method for the management of iatrogenic preterm premature rupture of the membranes. Fetal Diagn Ther
2002;17:8-10.
11. Briery CM, Veillon EW, Klauser CK, et al.
Women with preterm premature rupture of the
membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011;204:54.e1-5.
12. Nageotte MP, Freeman RK, Garite TJ,
Dorchester W. Prophylactic intrapartum amnioinfusion in patients with preterm premature
rupture of membranes. Am J Obstet Gynecol
1985;153:557-62.
13. Szabo I, Szilagyi A, Gacs E, Szekely J. Amnioinfusion for management of preterm prelabour
rupture of membranes. Lancet 1993;341:443-4.
14. Fisk NM, Ronderos-Dumit D, Soliani A, Nicolini U, Vaughan J, Rodeck CH. Diagnostic and
therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991;78:270-8.
15. Ogita S, Imanaka M, Matsumoto M, Oka T,
Sugawa T. Transcervical amnioinfusion of antibiotics: a basic study for managing premature
rupture of membranes. Am J Obstet Gynecol
1988;158:23-7.
16. Sadovsky Y, Amon E, Bade ME, Petrie RH.
Prophylactic amnioinfusion during labor complicated by meconium: a preliminary report. Am J
Obstet Gynecol 1989;161:613-7.
17. De Santis M, Scavo M, Noia G, et al. Transabdominal amnioinfusion treatment of severe
Obstetrics
www.AJOG.org
31. Gramellini D, Fieni S, Kaihura C, Faiola S,
Vadora E. Transabdominal antepartum amnioinfusion. Int J Gynaecol Obstet 2003;
83:171-8.
32. Ogunyemi D, Thompson W. A case controlled study of serial transabdominal amnioinfusions in the management of second trimester
oligohydramnios due to premature rupture of
membranes. Eur J Obstet Gynecol Reprod Biol
2002;102:167-72.
33. Vergani P, Locatelli A, Strobelt N, et al.
Amnioinfusion for prevention of pulmonary
hypoplasia in second-trimester rupture of
Research
1.e11